Merck, Simcere to Establish Drug Production Plant in Nanjing

Merck & Co. and Simcere Pharmaceutical Group (SCR) plan to establish a drug manufacturing plant in Nanjing, the head of Merck’s business in China said.

Merck’s joint venture in China with Simcere will be “fully integrated” by 2020, China operations president Michel Vounatsos told reporters in the Chinese city of Nanjing today.

To contact the reporter on this story: Bloomberg News at emailtv@bloomberg.net

To contact the editor responsible for this story: Jason Gale at j.gale@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.